Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: A study from North India

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue 4, 2014, Pages 287-292

  Gupta, Varun ^a   Kumar, Ashish ^a   Sharma, Praveen ^a   Tyagi, Pankaj ^a   Bansal, Naresh ^a   Singla, Vikas ^a   Arora, Anil ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

ALT; Antivirals; AST; BMI; CHC; ETR; EVR; G CSF; HCV; Hepatitis C virus; HIV; Interferon; Liver disease; NS; PCR; PEG IFN; RVR; Sustained viral response; SVR; TLC

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ALCOHOL ABUSE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INDIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PATIENT SELECTION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VIRUS LOAD;

EID: 84920741484     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.08.004     Document Type: Article

References (21)

1. Jawaid A., Khuwaja A.K. Treatment and vaccination for hepatitis C: present and future. JAyub Med Coll Abbottabad JAMC 2008 Mar, 20(1):129-133.
2. Zein N.N., Rakela J., Krawitt E.L., Reddy K.R., Tominaga T., Persing D.H. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996 Oct 15, 125(8):634-639.
3. Foster G.R. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opin Pharmacother 2003 May, 4(5):685-691.
4. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B., American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update. Hepatol Baltim Md 2009 Apr, 49(4):1335-1374.
5. Idrees M., Riazuddin S. Astudy of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009, 9:5.
6. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 Sep 22, 358(9286):958-965.
7. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEngl J Med 2013 Jan 3, 368(1):34-44.
8. Liang T.J., Ghany M.G. Current and future therapies for hepatitis C virus infection. NEngl J Med 2013 May 16, 368(20):1907-1917.
9. Baldick C.J., Wichroski M.J., Pendri A., et al. Anovel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog 2010, 6(9):e1001086.
10. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 2004 Mar 2, 140(5):370-381.
11. Garg G., Kar P. Management of HCV infection: current issues and future options. Trop Gastroenterol Off J Dig Dis Found 2009 Mar, 30(1):11-18.
12. Slavenburg S., Weggelaar I., van Oijen M.G.H., Drenth J.P.H. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther 2009, 14(8):1139-1148.
13. Kogure T., Ueno Y., Fukushima K., et al. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol WJG 2008 Dec 21, 14(47):7225-7230.
14. Freshwater D.A., O'Donnell K., Mutimer D.J. Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. JViral Hepat 2008 Feb, 15(2):115-119.
15. Sood A., Midha V., Sood N., Bansal M. Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis. Indian J Gastroenterol Off J Indian Soc Gastroenterol 2006 Dec, 25(6):283-285.
16. Liu C.-H., Liu C.-J., Lin C.-L., et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis Off Publ Infect Dis Soc Am 2008 Nov 15, 47(10):1260-1269.
17. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. JHepatol 2008 Oct, 49(4):634-651.
18. Tohra S.K., Taneja S., Ghosh S., et al. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. Dig Dis Sci 2011 Aug, 56(8):2449-2455.
19. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 Apr, 126(4):1015-1023. [discussion 947].
20. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 Mar 2, 140(5):346-355.
21. Lindahl K., Stahle L., Bruchfeld A., Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatol Baltim Md 2005 Feb, 41(2):275-279.